VXRT Vaxart, Inc.
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference Vaxart (OTCMKTS:VXRT) Chief Executive Officer Steve Lo outlined the company’s oral vaccine platform, its government-funded COVID-19 study and development opportunities in norovirus and influenza during an H.C. Wainwright conference presentation. Lo said Vaxart’s recombinant adenovirus type 5, or Ad | ||
Vaxart Inc (VXRT) (Q2 2026) Earnings Call Highlights: Oral COVID Vaccine Shows Promise, Cash ... Vaxart reports positive safety data from its oral COVID-19 vaccine sentinel cohort while managing a reduced cash position and navigating BARDA-controlled data timelines. | ||
 Vaxart Q2 Earnings Call Highlights Vaxart (OTCMKTS:VXRT) said it has reported positive 12-month safety data from the 400-participant Sentinel cohort of its Phase II-B COVID-19 vaccine trial and remains on track to disclose top-line data from the larger, approximately 5,000-participant main cohort in the first half of 2027. The compa | ||
 Vaxart, Inc. Q2 2026 Earnings Call Summary Moby summary of Vaxart, Inc.'s Q2 2026 earnings call | ||
Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now Vaxart (OTCMKTS:VXRT) held its 2026 Annual Meeting of Stockholders, where investors re-elected the company’s full slate of directors, ratified its auditor and rejected the company’s non-binding advisory proposal on executive compensation. Mark Watson, Vaxart’s lead independent director and chair of | ||